Modest Predictive Power for HbA1c in Atherosclerotic CVD Risk

This article originally appeared here.
Share this content:
Modest Predictive Power for HbA1c in Atherosclerotic CVD Risk
Modest Predictive Power for HbA1c in Atherosclerotic CVD Risk

THURSDAY, Sept. 10, 2015 (HealthDay News) -- In the context of conventional cardiovascular disease (CVD) risk factors, hemoglobin A1c (HbA1c) has a modest effect on predicted atherosclerotic CVD risk, according to a study published online Sept. 8 in Circulation: Cardiovascular Quality and Outcomes.

Jamie A. Jarmul, from the University of North Carolina at Chapel Hill, and colleagues examined the effect of HbA1c on CVD risk in the context of other CVD risk factors. HbA1c and other CVD risk factor measurements were analyzed in 2,000 individuals aged 40 to 79 years without preexisting diabetes mellitus or CVD. For a set of example scenarios, post-test 10-year atherosclerotic CVD risk was calculated incorporating the actual versus predicted HbA1c, according to established methods.

The researchers found that significant predictors in the model included age, sex, race/ethnicity, and traditional cardiovascular risk factors, with the expected HbA1c distribution significantly higher in non-Hispanic black, non-Hispanic Asian, and Hispanic individuals versus non-Hispanic whites/others. A modest effect was seen on post-test atherosclerotic CVD risk for incorporation of the expected HbA1c distribution into pretest atherosclerotic CVD risk. In the patient examples, depending on the scenario, HbA1c of <5.7 percent reduced post-test risk by 0.4 to 2.0 percent, while having HbA1c of ≥6.5 percent increased post-test risk by 1.0 to 2.5 percent.

"HbA1c has modest effects on predicted atherosclerotic CVD risk when considered in the context of conventional risk factors," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial
Editor's Perspective

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »